Lv1
30 积分 2025-08-14 加入
XBP1s Mediates Cross-resistance to Combination Treatment of CDK4/6 Inhibitors plus Endocrine Therapy in Breast Cancer
4小时前
已完结
Using Explainable AI to Characterize Features in the Mirai Mammographic Breast Cancer Risk Prediction Model
16天前
已完结
Using Explainable AI to Characterize Features in the Mirai Mammographic Breast Cancer Risk Prediction Model
17天前
已关闭
Development and Validation of a Preoperative Magnetic Resonance Imaging Radiomics–Based Signature to Predict Axillary Lymph Node Metastasis and Disease-Free Survival in Patients With Early-Stage Breast Cancer
24天前
已完结
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
1个月前
已完结
Integrating Machine Learning-Predicted Circulating Tumor Cells (CTCs) and circulating tumor DNA (ctDNA) in Metastatic Breast Cancer: a proof of principle study on endocrine resistance profiling
1个月前
已完结
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy
1个月前
已完结
Abstract GS03-13: Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis
1个月前
已关闭
Inavolisib: First Approval
1个月前
已完结
PI3K Inhibitors in Breast Cancer Therapy
1个月前
已完结
皖公网安备34019202002308
